NO20074616L - Antistoffer mot Candida antigener - Google Patents

Antistoffer mot Candida antigener

Info

Publication number
NO20074616L
NO20074616L NO20074616A NO20074616A NO20074616L NO 20074616 L NO20074616 L NO 20074616L NO 20074616 A NO20074616 A NO 20074616A NO 20074616 A NO20074616 A NO 20074616A NO 20074616 L NO20074616 L NO 20074616L
Authority
NO
Norway
Prior art keywords
antibodies
candida antigens
domain antibodies
candida
antigens
Prior art date
Application number
NO20074616A
Other languages
English (en)
Inventor
Antonio Cassone
Flavia De Bernardis
Heiqun Liu
Steven Grant
Original Assignee
Flavia De Bernardis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0505489A external-priority patent/GB0505489D0/en
Priority claimed from GBGB0519883.3A external-priority patent/GB0519883D0/en
Application filed by Flavia De Bernardis filed Critical Flavia De Bernardis
Publication of NO20074616L publication Critical patent/NO20074616L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

SAMMENDRAG Foreliggende oppfinnelse angår domeneantistoffer. Den angår spesielt domeneantistoffer (dAb'er) som gjenkjenner virulenstrekk hos Candida spp. og gir passiv beskyttelse mot kandidose.
NO20074616A 2005-03-18 2007-09-12 Antistoffer mot Candida antigener NO20074616L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0505489A GB0505489D0 (en) 2005-03-18 2005-03-18 Antibodies
GBGB0519883.3A GB0519883D0 (en) 2005-09-29 2005-09-29 Antibodies
PCT/GB2006/000843 WO2006097689A2 (en) 2005-03-18 2006-03-10 Antibodies against candida antigens

Publications (1)

Publication Number Publication Date
NO20074616L true NO20074616L (no) 2007-11-27

Family

ID=36808786

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074616A NO20074616L (no) 2005-03-18 2007-09-12 Antistoffer mot Candida antigener

Country Status (12)

Country Link
US (1) US8092800B2 (no)
EP (1) EP1863845A2 (no)
JP (1) JP2008533115A (no)
KR (1) KR20080003351A (no)
AU (1) AU2006224438A1 (no)
CA (1) CA2601115A1 (no)
EA (1) EA200701766A1 (no)
IL (1) IL185781A0 (no)
MA (1) MA29394B1 (no)
MX (1) MX2007011356A (no)
NO (1) NO20074616L (no)
WO (1) WO2006097689A2 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007011356A (es) 2005-03-18 2008-03-10 Domantis Ltd Anticuerpos contra antigenos de candida.
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US20090081196A1 (en) * 2007-02-16 2009-03-26 Istituto Superiore Di Sanita Medicaments for fungal infections
AU2009306424A1 (en) * 2008-10-21 2010-04-29 Domantis Limited Ligands that have binding specificity for DC-SIGN
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
JP2014515757A (ja) * 2011-04-21 2014-07-03 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ 真菌感染症のペプチド及び結合型ワクチン
CN107663239A (zh) * 2016-12-28 2018-02-06 天津天锐生物科技有限公司 一种识别hla‑a2/nlvpmvatv的单域抗体
CN112552402B (zh) * 2018-09-27 2022-08-12 暨南大学 一种抗人egfr的纳米抗体与应用
WO2020130838A2 (en) * 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
CN112646035B (zh) * 2020-12-25 2022-06-24 暨南大学 Egfr的亲和力成熟结合蛋白及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE291586T1 (de) 1999-02-01 2005-04-15 Schering Ag Humanes antibiotisches protein
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003072736A2 (en) 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
WO2004041863A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
JP2006517789A (ja) * 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
JP2007528201A (ja) * 2003-03-14 2007-10-11 ファルマシア・コーポレーション 癌治療のためのｉｇｆ−ｉ受容体に対する抗体
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
JP5634008B2 (ja) 2004-04-06 2014-12-03 アフィボディ・アーベー 新規の使用および方法
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
MX2007011356A (es) 2005-03-18 2008-03-10 Domantis Ltd Anticuerpos contra antigenos de candida.
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections

Also Published As

Publication number Publication date
MX2007011356A (es) 2008-03-10
AU2006224438A1 (en) 2006-09-21
US8092800B2 (en) 2012-01-10
CA2601115A1 (en) 2006-09-21
EA200701766A1 (ru) 2008-04-28
WO2006097689A2 (en) 2006-09-21
IL185781A0 (en) 2008-01-06
KR20080003351A (ko) 2008-01-07
EP1863845A2 (en) 2007-12-12
JP2008533115A (ja) 2008-08-21
WO2006097689A3 (en) 2007-03-15
MA29394B1 (fr) 2008-04-01
US20080193450A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
NO20074616L (no) Antistoffer mot Candida antigener
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA30945B1 (fr) Anticorps anti-tat226 et immunoconjugués
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EP2019825A4 (en) HEMMER OF THE REPRODUCTION OF HUMAN IMMUNE DEFICIENCY VIRUSES
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
PA8794201A1 (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA200901109A1 (ru) Применение n-фениламидинов в качестве гербицидов
EP2322562A4 (en) MONOCLONAL ANTIBODY AND IMMUNASSAY WITH IT
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
MA30922B1 (fr) Anticorps d'agonistes de trkb et leurs utilisations
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
EP1814913A4 (en) ANTIBODY-INDUCED CELL MEMBRANE INJURY
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
DK1987357T3 (da) Polypeptider, som genkendes af anti-Trichinella-antistoffer, og anvendelser deraf
CL2007002370A1 (es) Conjugado que consta de un anticuerpo anti-ccr5 y uno o mas peptidos antifusogenicos; composicion farmaceutica que lo comprende; metodo de preparacion; y su uso para tratar infecciones virales.
HN2006029142A (es) Proceso

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application